Sustainability Disclosures | Takeda Pharmaceuticals
Sustainability Disclosures
Our ESG reporting is updated regularly aligned with our transparency polices, practices, and data.
We will continuously work to improve our data capture processes and reporting of ESG information, to demonstrate our commitment to transparency and our stakeholders.
We developed our corporate philosophy imperatives: Patient, People and Planet, which identify where Takeda must invest to deliver on our purpose, informed by an ESG materiality assessment of strategically important nonfinancial issues to our company and stakeholders. In FY2022, we evolved these imperatives to create a simplified sustainability framework and sustainability focus areas.
We measure our progress toward these imperatives and sustainability focus areas through our corporate philosophy metrics.
The information below provide links to our ESG disclosures and performance indicators under the categories of Patient, People, Planet and Values-Based Governance.
This information supplements our Annual Integrated Report. A complete list of the Metrics under each category can be found here.
Patient
Responsibly translate science into highly innovative, life-transforming medicines and vaccines
Our approach: Responsibly translate science into highly innovative, life-changing medicines and vaccines
Our approach to Bioethics: Ethics
More on what we do:
- More on what we do: Areas of Focus
Our Positions:
- More on what we do: Manufacturing
- Our Position on Falsified Medical Products
Accelerate access to improve lives worldwide
Our approach: Timely, Broad and Sustainable Access
More on what we do: Our U.S. Pricing Philosophy
Our Positions:
More on what we do:
People
- Our approach: Talent Management
- More on what we do regarding Talent recruitment and retention efforts for scientists and research and development personnel: SASB Index Report 2023
Our approach to Employee health, well-being and resilience: Talent Management
More on who we are: Global Environment, Health and Safety Policy
- Our approach to Diversity, Equity & Inclusion: Talent Management
- Our approach to Lifelong learning: Talent Management
Planet
Our Position: Our position on Climate Change
More on who we are: Global Environment, Health and Safety Policy
Our stories: Decarbonizing
Historical Record of Takeda Voluntary Offset and EAC Purchases
More on what we do:
Our approach: Our Commitment to the Planet
Our Approach to Key Sustainability Topics: Water Stewardship, Plastics, Biodiversity, Pharmaceuticals in the Environment and Eco-Design
More on who we are: Global Environment, Health and Safety Policy
Our stories:
Our Positions:
Values-based governance
- Our approach: Corporate Governance
More on who we are:
Information on Annual Shareholders Meetings, including Notices of Resolutions and Results of the Exercise of Voting Rights: Annual Shareholders Meetings
Information on total rewards and compensation, see Takeda’s Executive Compensation Overview and Corporate Governance Report
Our approach to Quality management: Ethics
Takeda products with safety alerts can be found in the FDA MedWatch Safety Alerts for Human Medical Products database
Historical product recalls can be found in the FDA Drug Recalls database
Our approach: Suppliers
More on who we are: Takeda Supplier Code of Conduct
- Our approach: Ethics (including Medical Ethics, Bioethics and Human Rights)
More on who we are:
More about what we do on Safety of Clinical Trial Participants: SASB Index Report 2023
More on our approach to human rights:
Our approach: Risk & Crisis Management
Matters related to internal controls and risk management rules: Corporate Governance Report
- Our approach: Corporate Giving
More about what we do: